A randomized, placebo-controlled trial, to evaluate the safety and immunogenicity of the COVID-19 vaccine, a measles vector-based vaccine candidate against COVID-19 in healthy volunteers consisting of an unblinded dose escalation and a blinded treatment p

Study title: 
A randomized, placebo-controlled trial, to evaluate the safety and immunogenicity of the COVID-19 vaccine, a measles vector-based vaccine candidate against COVID-19 in healthy volunteers consisting of an unblinded dose escalation and a blinded treatment p
Long title: 
A randomized, placebo-controlled trial, to evaluate the safety and immunogenicity of the COVID-19 vaccine, a measles vector-based vaccine candidate against COVID-19 in healthy volunteers consisting of an unblinded dose escalation and a blinded treatment phase.
Date receipt dossier: 
22 Jun 2020
EU record number: 
COVID-19-101
EudraCT number: 
2020-002973-89
Pharmaceutical study code: 
MV-SARS-Cov2
Company / Sponsor: 
Institut Pasteur & Themis Bioscience GmbH
Phase: 
I
Treated organism: 
Humans
Indication category: 
Infectious disease
Disease: 
COVID-19
Therapeutic approach: 
Prevention
Genetic modification: 
Recombinant measles virus vaccine strain (Schwarz strain) expressing the Spike glycoprotein 1 from SARS-CoV2
Method of transfer of nucleic acid of interest: 
Not applicable
Administered biological material: 
Recombinant measles virus vaccine strain (Schwarz strain) expressing the Spike glycoprotein 1 from SARS-CoV2
Route of administration: 
Intramuscular
Locations in Belgium: 
SGS Belgium
Type of procedure: 
Contained use only
Current status: 
Under evaluation